

## Braftovi - (75 mg ; Capsule)

|                              |                                                                                                                                                                                                                             |                             |                     |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| <b>Generic Name</b>          | Encorafenib                                                                                                                                                                                                                 | <b>Innovator</b>            | Array BioPharma     |
| <b>Dosage</b>                | 75 mg ; Capsule                                                                                                                                                                                                             | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | Less Than 5                                                                                                                                                                                                                 | <b>Known Para IV Filers</b> | Less Than 5         |
| <b>Other ANDA developers</b> | Less Than 5                                                                                                                                                                                                                 | <b>Tentative Approvals</b>  | Less Than 5         |
| <b>Final Approvals</b>       | None                                                                                                                                                                                                                        | <b>Generic Launches</b>     | None                |
| <b>Indication</b>            | BRAFTOVI is a kinase inhibitor indicated, in combination with Binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. |                             |                     |
| <b>Complexities</b>          | Yes                                                                                                                                                                                                                         |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.